Skip to main content
SpringerLink
Log in

Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The purpose of these studies was to determine the optimal conditions and limitations for the eradication of spontaneous melanoma metastases by the systemic administration of liposomes containing MTP-PE. Mice whose primary melanoma had been excised were given i.v. injections of liposomes at various schedules. Optimal treatment was achieved by twice weekly administration for 4 weeks (eight i.v. injections). Bioassays failed to reveal the presence of melanoma cells in lungs of mice surviving to day 250 of the experiment. The success of liposome treatment of metastases diminished when the first i. v. injection of liposomes-MTP-PE commenced on day 10 after surgical excision of the local melanoma, as compared with day 3 or day 7 after surgery. We conclude that the major limitation for macrophage-mediated destruction of metastases is the number of tumor cells in the lesions. Because of this limitation, it is unlikely that the systemic activation of macrophages could be used as a single modality for treatment of advanced metastases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alving CR (1983) Delivery of liposome-encapsulated drugs to macrophages. Pharmacol Ther 22:407

    Google Scholar 

  2. Deodhar SD, Barna BP, Edinger M, Chiang T (1982) Inhibition of lung metastases by liposomal immunotherapy in a murine fibrosarcoma model. J Biol Response Mod 1:27

    Google Scholar 

  3. Fidler IJ (1980) Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. Science 208:1469

    Google Scholar 

  4. Fidler IJ (1981) The in situ induction of tumoricidal activity in alveolar macrophages by liposomes containing muramyl dipeptide is a thymus-independent process. J Immunol 127:1719

    Google Scholar 

  5. Fidler IJ, Kleinerman ES (1984) Lymphokine-activated human blood monocytes destroy tumor cells but not normal cells under cocultivation conditions. J Clin Oncol 2 (8):937

    Google Scholar 

  6. Fidler IJ, Poste G (1982) Macrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic disease. Springer Semin Immunopathol 5:161

    Google Scholar 

  7. Fidler IJ, Schroit AJ (1984) Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: In situ activation of macrophages and therapy of spontaneous cancer metastasis. J Immunol 133 (1):515

    Google Scholar 

  8. Fidler IJ, Raz A, Fogler WE, Kirsh R, Bugelski P, Poste G (1980) The design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. Cancer Res 40:4460

    Google Scholar 

  9. Fidler IJ, Sone S, Fogler WE, Barnes ZL (1981) Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injections of liposomes containing muramyl dipeptide. Proc Natl Acad Sci USA 78:1680

    Google Scholar 

  10. Fidler IJ, Sone S, Fogler WE, Smith D, Braun DG, Tarcsay L, Gisler RJ, Schroit AJ (1982) Efficacy of liposomes containing a lipophilic muramyl dipeptide derivative for activating the tumoricidal properties of alveolar macrophages in vivo. J Biol Response Mod 1:43

    Google Scholar 

  11. Fidler IJ, Barnes Z, Fogler WE, Kirsh R, Bugelski P, Poste G (1982) Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. Cancer Res 42:496

    Google Scholar 

  12. Fidler IJ, Fogler WE, Tarcsay L, Schumann G, Braun DG, Schroit AJ (1983) Systemic activation of macrophages and treatment of cancer metastasis by liposomes containing hydrophilic or lipophilic muramyl dipeptide. In: Advances in immunopharmacology, vol. 2, Pergamon Press: Oxford, p 235

    Google Scholar 

  13. Fogler WE, Fidler IJ (1985) Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res 45:14

    Google Scholar 

  14. Fogler WE, Raz A, Fidler IJ (1980) In situ activation of murine macrophages by liposomes containing lymphokines. Cell Immunol 53:214

    Google Scholar 

  15. Griswold DP Jr (1972) Consideration of the subcutaneously implanted B16 melanoma as a screening model for potential anticancer agents. Cancer Chemother Rep 3:315

  16. Hart IR (1979) The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol 97:587

    Google Scholar 

  17. Key ME, Talmadge JE, Fogler WE, Bucana C, Fidler IJ (1982) Isolation of tumoricidal macrophages from lung melanoma metastases of mice treated systemically with liposomes containing a lipophilic derivative of muramyl dipeptide. J Natl Cancer Inst 69:1189

    Google Scholar 

  18. Kleinerman ES, Schroit AJ, Fogler WE, Fidler IJ (1983) Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. J Clin Invest 72:1

    Google Scholar 

  19. Kleinerman ES, Erickson KL, Schroit AJ, Fogler WE, Fidler IJ (1983) Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 43:2010

    Google Scholar 

  20. Kleinerman ES, Zicht R, Sarin PS, Gallo RC, Fidler IJ (1984) Constitutive production and release of a lymphokine with macrophage-activating factor activity distinct from gamma-interferon by a human T-cell leukemia viruspositive cell line. Cancer Res 44:4470

    Google Scholar 

  21. Lopez-Berestein G, Mehta K, Mehta R, Juliano RL, Hersh EM (1983) The activation of human monocytes by liposome-encapsulated muramyl dipeptide analogues. J Immunol 130:1500

    Google Scholar 

  22. Lopez-Berestein G, Milas L, Hunter N, Mehta K, Eppstein D, VanderPas MA, Mathews TR, Hersh EM (1984) Prophylaxis and treatment of experimental lung metastases in mice after treatment with liposome encapsulated 6-O-steroyl-N-acetylmuramyl-L-aminobutyryl-D-isoglutamine. Clin Exp Metastasis 2 (2):336

    Google Scholar 

  23. Mehta K, Lopez-Berestein G, Hersh EM, Juliano RL (1982) Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J Reticuloendothel Soc 32:155

    Google Scholar 

  24. Nicolau C, Paraf A (eds), (1981) Liposomes, drugs and immunocompetent cell functions, Academic Press, London

    Google Scholar 

  25. Phillips NC, Mora ML, Chedid L, Lefrancier P, Bernard JM (1985) Activation of tumoricidal activity and eradication of experimental metastases by freeze-dried liposomes containing a new lipophilic muramyl dipeptide derivative. Cancer Res 45:128

    Google Scholar 

  26. Poste G, Kirsh R, Fogler W, Fidler IJ (1979) Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res 39:881

    Google Scholar 

  27. Poste G, Bucana C, Raz A, Bugelski P, Kirsh R, Fidler IJ (1982) Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Cancer Res 42:1412

    Google Scholar 

  28. Poste G, Kirsh R, Bugelski P (1984) Liposomes as a drug delivery system in cancer therapy. In: Sunkara P (ed) Novel approaches to cancer chemotherapy. Academic Press, New York, p 323

    Google Scholar 

  29. Saiki I, Fidler IJ (1985) Synergistic activation by recombinant mouse gamma-interferon and muramyl dipeptide of tumoricidal properties in mouse macrophages. J Immunol 135:684

    Google Scholar 

  30. Schroit AJ, Fidler IJ (1982) Effects of liposome structure and lipid composition on the activation of the tumoricidal properties of macrophages by liposomes containing muramyl dipeptide. Cancer Res 42:161

    Google Scholar 

  31. Schroit AJ, Galligioni E, Fidler IJ (1983) Factors influencing the in situ activation of macrophages by liposomes containing muramyl dipeptide. Biol Cell 47:87

    Google Scholar 

  32. Schroit AJ, Hart IR, Madsen J, Fidler IJ (1983) Selective delivery of drugs encapsulated in liposomes: Natural targeting to macrophages involved in varius disease states. J Biol Response Mod 2:97

    Google Scholar 

  33. Sone S, Fidler IJ (1980) Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages. J Immunol 125:2454

    Google Scholar 

  34. Sone S, Fidler IJ (1981) In vitro activation of tumoricidal properties in rat alveolar macrophages by synthetic muramyl dipeptide encapsulated in liposomes. Cell Immunol 57:42

    Google Scholar 

  35. Sone S, Tsubura E (1982) Human alveolar macrophages: Potentiation of their tumoricidal activity by liposome-encapsulated muramyl dipeptide. J Immunol 129:1313

    Google Scholar 

  36. Sone S, Poste G, Fidler IJ (1980) Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. J Immunol 124:2197

    Google Scholar 

  37. Talmadge JE, Key M, Fidler IJ (1981) Macrophage content of metastatic and nonmetastatic rodent neoplasms. J Immunol 126:2245

    Google Scholar 

  38. Thomas DG, Breslow N, Gart JJ (1977) Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res 10:373

    Google Scholar 

  39. Xu ZL, Bucana CD, Fidler IJ (1984) In vitro activation of murine Kupffer cells by lymphokines or endotoxins to lyse syngeneic tumor cells. Am J Pathol 117:372

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cell Biology (173), The University of Texas, M. D. Anderson Hospital and Tumor Institute at Houston, 6723 Bertner Avenue, 77030, Houston, Texas, USA

    Isaiah J. Fidler

Authors
  1. Isaiah J. Fidler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fidler, I.J. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine. Cancer Immunol Immunother 21, 169–173 (1986). https://doi.org/10.1007/BF00199357

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00199357

Keywords

Search

Navigation